Hyderabad-based drug maker Aurobindo Pharmaceuticals said in a filing with the Bombay Stock Exchange that has received temporary approval for Tenofovir Disoproxil Fumarate tablets, 300 mg from the US Food and Drug Administration.
Tenofovir Disoproxil Fumarate tablets, 300 mg is the generic equivalent of Gilead Science Inc's Viread Tablets 300mg and falls under the anti-retroviral segment.
It is indicated in combination with other anti-retroviral for the treatment of HIV-1 infection in adults. Aurobindo has obtained a license from Gilead to market Tenofovir products in 95 Developing and least developed countries.
Aurobindo now has a total of 91 abbreviated new drug application (ANDA) approvals from USFDA. Sixty-six of these are final and 25 are tentative, the filing said.
